Is this your company? Get featured or correct your listing →
Recent changes
- Jun 17, 2026Jun 17, 2026Kardigan Files S-1MEF, Clearing the Last Step Toward Its Biotech IPO Pulse story
Investors
Latest Pulse
- Sep 22, 2026This Fall's Biotech IPOs Are Splitting Into Pops And DropsRecent biotech IPO debuts have split sharply: Parabilis Medicines popped 66.75% and BillionToOne jumped 66.67% on debut, while Electra Therapeutics closed down nearly 12% this week -- a mixed signal inside one reopened window.→
- Aug 31, 2026Biotech Funding Held Its Ground While AI Took the OxygenGlobal biotech startup investment is tracking to its usual $36 billion to $40 billion range in 2026 despite the AI capital surge, with more than $6 billion of that going to AI-native drug discovery companies.→
- Aug 2, 2026Biotech IPOs Are Upsizing Mid-Roadmap in 2026Several of 2026's biotech IPOs have expanded their target raise between initial filing and pricing, a sign the sector's strong average return this year has pulled in enough demand that bankers are re-cutting deal size on the fly.→
- Jun 17, 2026Kardigan Files S-1MEF, Clearing the Last Step Toward Its Biotech IPOCardiovascular biotech Kardigan filed an S-1MEF with the SEC -- a short-form registration used to register additional shares immediately before an offering goes effective. The filing signals Kardigan's IPO is imminent, a sign the biotech listing window is creaking back open alongside tech.→
Coverage Timeline
newest firstAll Coverage
Related Companies
Kardigan FAQ
Who are Kardigan's investors?
Kardigan's investors include ARCH Venture Partners.